- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05526417
Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma
Pre-Operative ERAS® (Enhanced Recovery After Surgery): Randomized Feasibility Trial of Implementing Individualized Prehabilitation for People Undergoing Neo-Adjuvant Radiotherapy and Lower Limb Soft-Tissue Sarcoma Surgery
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To determine if a tailored prehabilitation program focusing on functional optimization of spared limb tissue in two groups of patients with localized, lower extremity soft tissue sarcoma, one with prehabilitation and one with equal attention and informational support, improves functional outcome as measure by the Toronto Extremity Salvage Score (TESS).
II. To identify the measures and metrics most responsive to the intervention using the (TESS), Six Minute Walk Test (6MWT), wearable Heel2Toe sensor technology, and daily step count.
III. To estimate recruitment, retention, adherence, and acceptability rates.
SECONDARY OBJECTIVES:
I. To compare changes in quality of life over time as a result of the prehabilitation intervention using the Edmonton Symptom Assessment Scale (ESAS), European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L) (Euroqol Group), the Patient Generated Index (PGI).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients perform personalized prehabilitation physical therapy exercises twice a day (BID) 5 days per week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery, attend telemedicine visits with a physical therapist once a week for 9 weeks, and receive educational materials. Patients undergo magnetic resonance imaging (MRI) and computed tomography (CT) at week 9.
ARM II: Patients receive educational materials and attend a telemedicine visit with a research assistant once a week for 8 weeks while receiving standard of care radiotherapy prior to standard of care surgery. Patients undergo MRI and CT at week 9.
After completion of study, patients are followed up at weeks 2, 6, and 12.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Recruiting
- Mayo Clinic in Arizona
-
Contact:
- Clinical Trial Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
Principal Investigator:
- Krista A. Goulding, MD, MPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically-proven deep soft tissue sarcoma (STS) of the lower extremity
- Localized
- Adults, 18 and older
- All gender types
- Subjects must be able to provide appropriate consent or have an appropriate representative available to do so
Exclusion Criteria:
- Soft tissue sarcomas that are in a superficial location relative to fascia
- Patients with metastatic disease (distant or nodal)
- Both and upper and lower extremity involvement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm I (prehabilitation physical therapy)
Patients perform personalized prehabilitation physical therapy exercises BID 5 days per week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery, attend telemedicine visits with a physical therapist once a week for 9 weeks, and receive educational materials.
Patients undergo MRI and CT at week 9.
|
Ancillary studies
Undergo MRI
Other Names:
Undergo CT
Other Names:
Receive educational materials
Other Names:
Receive prehabilitation physical therapy
Other Names:
Attend telemedicine visits
Other Names:
|
|
Active Comparator: Arm II (educational materials)
Patients receive educational materials and attend a telemedicine visit with a research assistant once a week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery.
Patients undergo MRI and CT at week 9.
|
Ancillary studies
Undergo MRI
Other Names:
Undergo CT
Other Names:
Receive educational materials
Other Names:
Attend telemedicine visits
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility as measured by recruitment, retention, adherence, and acceptability
Time Frame: Up to 22 weeks
|
Univariate descriptive statistics and frequency distributions will be calculated, as appropriate for all variables.
Baseline values for demographic, clinical, and outcome variables will be tabulated for the treatment groups.
|
Up to 22 weeks
|
|
Efficacy potential
Time Frame: Up to 22 weeks
|
Univariate descriptive statistics and frequency distributions will be calculated, as appropriate for all variables.
Baseline values for demographic, clinical, and outcome variables will be tabulated for the treatment groups.
Between-group effect sizes will be estimated for continuous outcomes.
|
Up to 22 weeks
|
|
Toronto Extremity Salvage Score
Time Frame: At 2, 6, and 12 weeks
|
This is a self-report measure comprising 30 items (23 for activities of daily living; 7 items for role participation).
Will use this measure, completed using observed performance for feasible items and self-report for the remaining items (getting in and out of a car, shopping; driving).
Univariate descriptive statistics and frequency distributions will be calculated, as appropriate for all variables.
Baseline values for demographic, clinical, and outcome variables will be tabulated for the treatment groups.
Between-group effect sizes will be estimated from a mixed model which considers the individual as a cluster with multiple measures per person.
|
At 2, 6, and 12 weeks
|
|
Functional walking capacity
Time Frame: At 2, 6, and 12 weeks
|
Functional walking capacity is defined as walking capacity needed for everyday activities of daily living such as shopping, traveling to and from work, and walking in the workplace or public buildings.
The six minute walk test (6MWT) is the gold standard measure for this.
The units are distance in meters covered during the test.
There is a standardized mobile application for measuring and data comes minute by minute to assess fatigability.
Univariate descriptive statistics and frequency distributions will be calculated, as appropriate for all variables.
|
At 2, 6, and 12 weeks
|
|
Gait quality
Time Frame: Up to 22 weeks
|
Gait quality will be measured during the 6MWT using a wearable developed by the team, Heel2Toe sensor.
The parameters of gait quality will include proportion of steps with as strong a heel strike pre-operatively, as well as distribution of cadence and of angular velocity.
Irregular stepping pattern is indicated by lack of heel strike, large variability in cadence, stride length, and angular velocity as indicated by coefficient of variation.
Univariate descriptive statistics and frequency distributions will be calculated, as appropriate for all variables.
|
Up to 22 weeks
|
|
Daily step count
Time Frame: Up to 22 weeks
|
Daily step count for the duration of the study will be obtained using the native accelerometer/gyroscope and pedometers available on both iPhone and android devices.
Will summarize this complex data using benchmarks of 1, 3, 5, 7, 9 (000 steps) based on meaningful physical activity targets.
Will measure the time to achieve these targets post-surgery.
These will be captured for the 9 week prehabilitation period and the post-surgery recovery period.
As indicated, will focus on steps taken outside of the house as "in house" steps tend to be of very low cadence.
For step counts, time to reach the benchmarks of 1, 3, 5, 7, 9 (000 steps) will be calculated and presented descriptively.
Univariate descriptive statistics and frequency distributions will be calculated, as appropriate for all variables.
|
Up to 22 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptom status
Time Frame: Up to 22 weeks
|
Symptom status will be assessed using the Edmonton Symptom Assessment Scale which assesses 7 symptoms including pain, fatigue, distress, and overall well-being.
Univariate descriptive statistics and frequency distributions will be calculated, as appropriate for all variables.
|
Up to 22 weeks
|
|
Global health related quality of life
Time Frame: Up to 22 weeks
|
Global health related quality of life will be measured using the 5-level EQ-5D version (Euroqol Group) and the Patient Generated Index will be used to assess quality of life.
Univariate descriptive statistics and frequency distributions will be calculated, as appropriate for all variables.
|
Up to 22 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Krista A. Goulding, MD, MPH, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Connective and Soft Tissue
- Sarcoma
- Health Services Administration
- Delivery of Health Care
- Investigative Techniques
- Therapeutics
- Health Services
- Health Care Facilities Workforce and Services
- Child Health Services
- Community Health Services
- Preventive Health Services
- Socioeconomic Factors
- Population Characteristics
- Rehabilitation
- Chemistry Techniques, Analytical
- Spectrum Analysis
- Patient Care Management
- Methods
- Early Intervention, Educational
- Educational Status
- Magnetic Resonance Spectroscopy
- Telemedicine
- Physical Therapy Modalities
Other Study ID Numbers
- GMROA2182 (Mayo Clinic in Arizona)
- NCI-2022-05583 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 21-002674 (Other Identifier: Mayo Clinic Institutional Review Board)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
ImmunityBio, Inc.CompletedUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part Sarcoma | Refractory Alveolar Soft Part SarcomaUnited States
-
University of WashingtonAadi Bioscience, Inc.TerminatedAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
Centre Oscar LambretCentre de traitement des données du Cancéropôle Nord-Ouest, Centre F. BACLESSE... and other collaboratorsNot yet recruitingSoft Tissue Sarcoma Adult | Soft Tissue Sarcoma of the Limb | Soft Tissue Sarcoma (Excluding GIST) | Soft Tissue Sarcoma of the Trunk and ExtremitiesFrance
-
Adcendo ApSRecruitingUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States, France, United Kingdom, Belgium, Germany
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceActive, not recruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAdvanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
Gulseren Demir KarakilicCompletedMusculoskeletal Diseases | Chronic PainTurkey (Türkiye)
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden